Brain iron deposition and whole-exome sequencing of non-Wilson's disease hypoceruloplasminemia in a family

Hellman, 2002, Ceruloplasmin metabolism and function, Annu Rev Nutr, 22, 439, 10.1146/annurev.nutr.22.012502.114457 Rouault, 2013, Iron metabolism in the CNS: implications for neurodegenerative diseases, Nat Rev Neurosci, 14, 551, 10.1038/nrn3453 Coffey, 2013, A genetic study of Wilson's disease in the United Kingdom, Brain, 136, 1476, 10.1093/brain/awt035 Walshe, 2005, Diagnostic significance of reduced serum caeruloplasmin concentration in neurological disease, Mov Disord, 20, 1658, 10.1002/mds.20628 Lirong, 2009, Hypoceruloplasminemia-related movement disorder without Kayser-Fleischer rings is different from Wilson disease and not involved in ATP7B mutation, Eur J Neurol, 16, 1130, 10.1111/j.1468-1331.2009.02733.x Aldecoa, 2008, Menkes disease: its clinical, biochemical and molecular diagnosis, Rev Neurol, 46, 446 Miyajima, 2003, Aceruloplasminemia, an iron metabolic disorder, Neuropathology, 23, 345, 10.1046/j.1440-1789.2003.00521.x Madsen, 2007, Copper and iron disorders of the brain, Annu Rev Neurosci, 30, 317, 10.1146/annurev.neuro.30.051606.094232 Bamshad, 2011, Exome sequencing as a tool for Mendelian disease gene discovery, Nat Rev Genet, 12, 745, 10.1038/nrg3031 Rehm, 2013, ACMG clinical laboratory standards for next-generation sequencing, Genet Med, 15, 733, 10.1038/gim.2013.92 Lim, 2013, Human brain atlas for automated region of interest selection in quantitative susceptibility mapping: application to determine iron content in deep gray matter structures, Neuroimage, 82, 449, 10.1016/j.neuroimage.2013.05.127 Steinhaus, 2021, MutationTaster2021, Nucleic Acids Res, 49, W446, 10.1093/nar/gkab266 Ng, 2003, SIFT: predicting amino acid changes that affect protein function, Nucleic Acids Res, 31, 3812, 10.1093/nar/gkg509 Collins, 2010, Metabolic crossroads of iron and copper, Nutr Rev, 68, 133, 10.1111/j.1753-4887.2010.00271.x Ayton, 2014, Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease, Mol Neurodegener, 9, 27, 10.1186/1750-1326-9-27 Grolez, 2015, Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease, BMC Neurol, 15, 74, 10.1186/s12883-015-0331-3 Li, 2016, Current drug managements of Wilson's disease: from west to east, Curr Neuropharmacol, 14, 322, 10.2174/1570159X14666151130222427 Chen, 2011, Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia, Nat Genet, 43, 1252, 10.1038/ng.1008 Glazov, 2011, Whole-exome re-sequencing in a family quartet identifies POP1 mutations as the cause of a novel skeletal dysplasia, PLoS Genet, 7, 10.1371/journal.pgen.1002027 Yang, 2014, HPV seropositivity joints with susceptibility loci identified in GWASs at apoptosis associated genes to increase the risk of Esophageal Squamous Cell Carcinoma (ESCC), BMC Cancer, 14, 501, 10.1186/1471-2407-14-501 Go, 2013, New susceptibility loci in MYL2, C12orf51 and OAS1 associated with 1-h plasma glucose as predisposing risk factors for type 2 diabetes in the Korean population, J Hum Genet, 58, 362, 10.1038/jhg.2013.14 Haelterman, 2014, A mitocentric view of Parkinson's disease, Annu Rev Neurosci, 37, 137, 10.1146/annurev-neuro-071013-014317 Tapryal, 2009, Reactive oxygen species regulate ceruloplasmin by a novel mRNA decay mechanism involving its 3'-untranslated region: implications in neurodegenerative diseases, J Biol Chem, 284, 1873, 10.1074/jbc.M804079200 Chen, 2015, Currently clinical views on genetics of Wilson's disease, Chin Med J: Englera, 128, 1826, 10.4103/0366-6999.159361 Marchi, 2019, Aceruloplasminemia: a severe neurodegenerative disorder deserving an early diagnosis, Front Neurosci, 13, 325, 10.3389/fnins.2019.00325 Wang, 2020, Generation of an induced pluripotent stem cell (iPSC) line (THSJTUi001-A) from a Wilson's disease patient harboring a homozygous Arg778Leu mutation in ATP7B gene, Stem Cell Res, 49